Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome

Journal of Autoimmunity

Volumn 90, Issue , 2018, Pages 76-83

  Chighizola, Cecilia Beatrice ^a,b   Pregnolato, Francesca ^b   Andreoli, Laura ^c   Bodio, Caterina ^a,b   Cesana, Laura ^b   Comerio, Chiara ^d   Gerosa, Maria ^a,e   Grossi, Claudia ^b   Kumar, Rajesh ^c   Lazzaroni, Maria Grazia ^c   Mahler, Michael ^f   Mattia, Elena ^g   Nalli, Cecilia ^c   Norman, Gary L ^f   Raimondo, Maria Gabriella ^a,e   Ruffatti, Amelia ^g   Tonello, Marta ^g   Trespidi, Laura ^d   Tincani, Angela ^c   Borghi, Maria Orietta ^a,b   Meroni, Pier Luigi ^a,b,e   more..

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^f INOVA DIAGNOSTICS INC   (United States)

^g UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti phospholipid antibodies; Anti phospholipid syndrome; Anti 2GPI domain 1 antibodies; Anti 2GPI domain 4 5 antibodies; Pregnancy morbidity

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BETA2 GLYCOPROTEIN DOMAIN 1 ANTIBODY; BETA2 GLYCOPROTEIN DOMAIN 4 ANTIBODY; BETA2 GLYCOPROTEIN DOMAIN 5 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE CONTROL STUDY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; PERINATAL MORBIDITY; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; THROMBOSIS; IMMUNOLOGY; METABOLISM; ODDS RATIO; PREDICTIVE VALUE; PREGNANCY; PREGNANCY COMPLICATION; PROGNOSIS; PROTEIN DOMAIN; RETROSPECTIVE STUDY;

ABORTION, SPONTANEOUS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; PROTEIN DOMAINS; RETROSPECTIVE STUDIES; THROMBOSIS;

EID: 85041900351     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2018.02.002     Document Type: Article

References (43)

1. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemostasis 4 (2006), 295–306.
2. Meroni, P.L., Borghi, M.O., Raschi, E., Tedesco, F., Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 7 (2011), 330–339.
3. Shoenfeld, Y., Krause, I., Kvapil, F., Sulkes, J., Lev, S., von Landenberg, P., et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J. Clin. Immunol. 23 (2003), 377–383.
4. Chighizola, C.B., Gerosa, M., Meroni, P.L., New tests to detect Antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr. Rheumatol. Rep., 16, 2014, 402.
5. Iverson, G.M., Victoria, E.J., Marquis, D.M., Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 15542–15546.
6. McNeeley, P.A., Dlott, J.S., Furie, R.A., Jack, R.M., Ortel, T.L., Triplett, D.A., et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb. Haemostasis 86 (2001), 590–595.
7. Reddel, S.W., Wang, Y.X., Sheng, Y.H., Krilis, S.A., Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J. Autoimmun. 15 (2000), 91–96.
8. de Laat, B., van Berkel, M., Urbanus, R.T., Siregar, B., de Groot, P.G., Gebbink, M.F., et al. Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 63 (2011), 3960–3968.
9. Ioannou, Y., Pericleous, C., Giles, I., Latchman, D.S., Isenberg, D.A., Rahman, A., Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 56 (2007), 280–290.
10. Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118 (2011), 4714–4718.
11. Andreoli, L., Chighizola, C.B., Nalli, C., Gerosa, M., Borghi, M.O., Pregnolato, F., et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheum. 67 (2015), 2196–2204.
12. Banzato, A., Pozzi, N., Frasson, R., De Filippis, V., Ruffatti, A., Bison, E., et al. Antibodies to domain I of β(2)Glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb. Res. 128 (2011), 583–586.
13. Meroni, P.L., Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools. Lupus 25 (2016), 905–910.
14. Ioannou, Y., Romay-Penabad, Z., Pericleous, C., Giles, I., Papalardo, E., Vargas, G., et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J. Thromb. Haemostasis 7 (2009), 833–842.
15. Agostinis, C., Durigutto, P., Sblattero, D., Borghi, M.O., Grossi, C., Guida, F., et al. A non complement-fixing antibody to β2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood 123 (2014), 3478–3487.
16. De Craemer, A.S., Musial, J., Devreese, K.M., Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J. Thromb. Haemostasis 14 (2016), 1779–1787.
17. Zhang, S., Wu, Z., Zhang, F., Li, Y., Role of anti-domain 1- β(2) glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: comment. J. Thromb. Haemostasis 14 (2016), 2076–2078.
18. Mahler, M., Albesa, R., Zohoury, N., Bertolaccini, M.L., Ateka-Barrutia, O., Rodriguez-Garcia, J.L., et al. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus 25 (2016), 911–916.
19. Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., et al. Antiphospholipid syndrome: antibodies to domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J. Thromb. Haemostasis 13 (2015), 782–787.
20. de Laat, B., Derksen, R.H., Urbanus, R.T., de Groot, P.G., IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005), 1540–1545.
21. Radin, M., Cecchi, I., Roccatello, D., Meroni, P.L., Sciascia, S., Prevalence and thrombotic risk assessment of anti-domain I beta 2 glycoprotein I antibodies: a systematic review. Sem. Thromb. Haemost, 2017, 10.1055/s-0037-1603936.
22. Meneghel, L., Ruffatti, A., Gavasso, S., Tonello, M., Mattia, E., Spiezia, L., et al. Detection of IgG anti-domain I beta2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin. Chim. Acta 446 (2015), 201–205.
23. de Laat, B., Pengo, V., Pabinger, I., Musial, J., Voskuyl, A.E., Bultink, I.E., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J. Thromb. Haemostasis 7 (2009), 1767–1773.
24. Mondejar, R., González-Rodríguez, C., Toyos-Sáenz de Miera, F.J., Melguizo-Madrid, E., Zohoury, N., Mahler, M., et al. Role of antiphospholipid score and anti-β2-glycoprotein I domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin. Chim. Acta 431 (2014), 174–178.
25. Pericleous, C., Ferreira, I., Borghi, O., Pregnolato, F., McDonnell, T., Garza-Garcia, A., et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One, 11, 2016, e0156407, 10.1371/journal.pone.0156407.
26. Andreoli, L., Nalli, C., Motta, M., Norman, G.L., Shums, Z., Encabo, S., et al. Anti-β₂-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?. Ann. Rheum. Dis. 70 (2011), 380–383.
27. Iverson, G.M., von Mühlen, C.A., Staub, H.L., Lassen, A.J., Binder, W., Norman, G.L., Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J. Autoimmun. 27 (2006), 266–271.
28. Arvieux, J., Renaudineau, Y., Mane, I., Perraut, R., Krilis, S.A., Youinou, P., Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb. Haemostasis 87 (2002), 599–605.
29. Ambrozic, A., Avcin, T., Ichikawa, K., Kveder, T., Matsuura, E., Hojnik, M., et al. Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int. Immunol. 14 (2002), 823–830.
30. Pengo, V., Ruffatti, A., Tonello, M., Hoxha, A., Bison, E., Denas, G., et al. Antibodies to domain 4/5 (Dm4/5) of β2-glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb. Res. 136 (2015), 161–163.
31. Pengo, V., Tripodi, A., Reber, G., Rand, J.H., Ortel, T.L., Galli, M., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J. Thromb. Haemostasis 7 (2009), 1737–1740.
32. Tincani, A., Allegri, F., Balestrieri, G., Reber, G., Sanmarco, M., Meroni, P., et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb. Res. 114 (2004), 553–558.
33. Pierangeli, S.S., Favaloro, E.J., Lakos, G., et al. Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin. Chim. Acta 413 (2012), 358–360.
34. McNamee, R., Confounding and confounders. Occup. Environ. Med. 60 (2003), 227–234.
35. Fox, J., Monette, G., Generalized collinearity diagnostics. JASA 87 (1992), 178–183.
36. Krämer, W., Sonnberger, H., The Linear Regression Model under Test. 1986, Physica-Verlag, Heidelberg, Germany.
37. Salafia, C.M., Cowchock, F.S., Placental pathology and antiphospholipid antibodies: a descriptive study. Am. J. Perinatol. 14 (1997), 435–441.
38. Sebire, N.J., Fox, H., Backos, M., Rai, R., Paterson, C., Regan, L., Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum. Reprod. 17 (2002), 1067–1071.
39. Viall, C.A., Chamley, L.W., Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun. Rev. 14 (2015), 446–471.
40. Chighizola, C.B., Gerosa, M., Trespidi, L., Di Giacomo, A., Rossi, F., Acaia, B., et al. Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expet Rev. Clin. Immunol. 10 (2014), 1505–1517.
41. Bouvier, S., Cochery-Nouvellon, E., Lavigne-Lissalde, G., Mercier, E., Marchetti, T., Balducchi, J.P., et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 123 (2014), 404–413.
42. Ruffatti, A., Salvan, E., Del Ross, T., Gerosa, M., Andreoli, L., Maina, A., et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb. Haemostasis 112 (2014), 727–735.
43. Bertolaccini, M.L., Andrade, D., Lakos, G., Willis, R., Pengo, V., Banzato, A., et al. Antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) core laboratory validation exercise: comparison of enzyme-linked immunosorbant assay (ELISA) and chemiluminescence immunoassay (CIA). Arthritis Rheum., 67, 2015.